Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The AHA 2026 Scientific Sessions are packed with landmark trial readouts that could redefine cardiovascular care. Key highlights include intensive BP control trials in stroke survivors and diabetics, statin discontinuation data in older adults, and novel therapies targeting inflammation and lipoprotein(a). GLP-1 agonists and AI-powered smartwatch ECGs also take center stage.
The American Heart Association (AHA) 2026 Scientific Sessions (Nov. 6–9, Chicago) are set to deliver a wave of high-stakes cardiovascular trial results that could reshape clinical practice. Leading the charge are the OPTIMAL-Stroke and OPTIMAL-Diabetes trials, which test whether pushing systolic blood pressure below 120 mmHg benefits ischemic stroke survivors and high-risk type 2 diabetes patients — two groups notably left out of the landmark SPRINT trial that redefined hypertension guidelines in 2017.
Also under scrutiny: the STREAM trial, which will offer the most robust data yet on whether older adults without cardiovascular disease face harm if they stop taking statins. Meanwhile, long-term follow-up data from the ISCHEMIA and COURAGE trials will revisit whether early invasive coronary strategies (stenting or bypass) actually improve outcomes in stable ischemic heart disease.
On the innovation front, the ZEUS trial (ziltivekimab, an IL-6 blocker) and Lp(a)HORIZON trial (pelacarsen) will present full cardiovascular outcomes data — despite already-disappointing topline results. GLP-1 agonist orforglipron's effect on obstructive sleep apnea and AI-enabled smartwatch ECGs for detecting heart dysfunction round out a packed agenda.
Key Takeaways:
Why it matters: These trials collectively address some of the biggest unanswered questions in cardiology — from who benefits most from aggressive BP control to whether cutting-edge therapies and digital tools can meaningfully reduce cardiovascular risk at scale.
